Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enitociclib in advanced hematological malignancies
NCT02745743Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of enitociclib in hematologic neoplasms (2 arms), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Phase 2 Dose up to 30 months and 3 more. Started Jun 2016; status: completed.
02
Drugs
enitociclib
03
Conditions
hematologic neoplasms
Beyond the preview
Go deeper on NCT02745743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745743.